Key result
Adjunctive Astragalus-Salvia miltiorrhiza linked to ~9% lower LDL-C at 5 years vs standard care alone.
Why the study?
The long-term efficacy and safety of the Astragalus-Salvia miltiorrhiza botanical drug pair as adjunctive therapy for stable coronary artery disease and prediction of frequent readmissions were not well established.
Does Astragalus-Salvia miltiorrhiza (ASM) botanical drug pair added to standard care improve biochemical parameters and alleviate symptoms in patients with stable coronary artery disease?
Cohort (n=686)
No
Does Astragalus-Salvia miltiorrhiza (ASM) botanical drug pair added to standard care improve biochemical parameters and alleviate symptoms in patients with stable coronary artery disease?
Astragalus-Salvia miltiorrhiza adjunctive therapy safely improves lipid profiles, stabilizes heart rate, and alleviates chest tightness in patients with stable coronary artery disease.
Answers are grounded in this paper and cite their sources.
May support lipid improvement in stable CAD without safety signals; leaves open confirmation via randomized trials.
Objective To evaluate the long-term efficacy and safety of the Astragalus-Salvia miltiorrhiza (ASM) botanical drug pair as an adjunctive therapy for stable coronary artery disease (SCAD) and to develop a prognostic nomogram for frequent readmissions. Methods This real-world retrospective cohort study included 686 SCAD patients (343 receiving ASM plus standard care and 343 receiving standard care alone). Inverse probability of treatment weighting (IPTW) was applied to balance covariates. After a 5-year follow-up, biochemical parameters, primarily low-density lipoprotein cholesterol (LDL-C), and safety profiles were compared. Furthermore, multivariable logistic regression was used to construct a nomogram predicting frequent readmissions (≥3 times), and symptom networks were analyzed via the Apriori algorithm to evaluate symptom alleviation. Results At the 5-year follow-up, compared to controls, the ASM group exhibited significantly reduced LDL-C, total cholesterol (TC), triglycerides (TG), heart rate, and monocytes, alongside elevated high-density lipoprotein cholesterol (HDL-C), free triiodothyronine (FT3), and free thyroxine (FT4) (all P < 0.05). Hepatic and renal functions remained unaffected ( P > 0.05). Notably, stroke history emerged as the primary independent risk factor ( P < 0.001) for frequent readmissions. The nomogram integrating stroke history, age, diastolic blood pressure, FT3, and hemoglobin demonstrated excellent calibration. Symptom network analysis identified “chest tightness” as the core symptom alleviated by ASM. Conclusion ASM adjunctive therapy safely improves lipid profiles, stabilizes heart rate, and alleviates chest tightness in SCAD. The proposed nomogram offers a reliable tool for risk stratification, providing real-world evidence to optimize the integrative management of SCAD. Clinical Trial Registration https://itmctr.ccebtcm.org.cn/mgt/dashboard , identifier TMCTR2025000058.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) conducted a cohort in Stable coronary artery disease (SCAD) (n=686). Astragalus-Salvia miltiorrhiza (ASM) botanical drug pair vs. Standard care alone was evaluated on Change in LDL-C levels from baseline to the end of the 5-year observation window (p=0.003). Adjunctive therapy with the Astragalus-Salvia miltiorrhiza botanical drug pair significantly reduced median LDL-C levels to 1.97 mmol/L compared to 2.17 mmol/L with standard care alone over 5 years.
Synapse has enriched 10 related papers. Consider them for comparative context: